This Week in Peptides
A weekly, physician-minded read on peptide regulation, safety, and research — what happened, why it matters, and what it means for you.
The Political Push for Faster Peptide Access Collides With a Sterility Recall
A senator wants faster peptide access. A licensed pharmacy just recalled vials over a sterility gap. This week showed how far apart peptide policy and peptide practice still are. On October 20…
A Peptide Compounding Policy Reaches the White House, as a New Investigation Surfaces Patient-Harm Reports
Regulators are easing peptide rules. Patients are describing migraines, numbness, and panic attacks. A policy that would let compounding pharmacies make some popular peptides is now sitting with the White House for…
What a Biologic Ruling Would Actually Change, and the Bigger Compounding Vote Already Taking Shape
Twelve years vs. five: the exclusivity gap one pending ruling could open for a weight-loss drug. It was a quiet week for new rulings or warning letters — but two pieces of…
Retatrutide’s First Phase 3 Results Are In, and the Compounding Rulebook Still Isn’t Written
A new weight-loss drug's legal status is still undecided — its first full phase 3 data just published. Two updates this week sit on opposite ends of the same story. Eli Lilly's…
A Warning Letter for a Major Compounder, and Retatrutide’s Case Now Sits With the Judges
The exact same phrase, copied into hundreds of "personalized" prescriptions. The FDA noticed. Two updates matter this week if you're weighing peptide or GLP-1 therapy. The FDA warned Empower Pharmacy, one of…
Retatrutide’s Day in Court, and Three Ways the Ruling Could Go
Tomorrow, September 24, the Seventh Circuit hears oral argument in Eli Lilly and Company v. Robert F. Kennedy, Jr., the case over whether retatrutide is legally a drug or a biologic. We…
Retatrutide Goes to the Seventh Circuit, and How to Vet a Telehealth Provider
Tomorrow, a federal appeals court hears the case that decides whether retatrutide, Eli Lilly's next-generation obesity drug, is legally a "drug" or a "biologic." That label settles whether any version of it…
A Third Texas Compounder Recall, and the China-to-Peptide Pipeline
A third Texas pharmacy in a month recalled injectable glutathione over endotoxin contamination. Separately, investigators are tracing former fentanyl-precursor manufacturers into the U.S. peptide supply chain.
A New Evidence-Gap Study, and Lilly’s Two-Front Retatrutide Fight
A UCLA-led review of 565 studies found peptide marketing outpaces the science. Meanwhile, Eli Lilly is fighting both the FDA and gray-market sellers over retatrutide.
The FDA’s Warning-Letter Sweep, and a New Clue About How GLP-1s Work
The FDA warned five online peptide sellers that “research use only” labels don’t hold up. And a Yale study upends conventional wisdom about GLP-1s.